UNSPSC 51162040: Beclometasone dipropionate/Formoterol fumarate/Glycopyrronium bromide

Beclomethasone/formoterol/glycopyrronium combination at 100:6:12.5 combination ratio was a balanced drug mixture leading to very strong synergistic effect on relaxation of medium bronchi and middle to very strong synergy in small airways.

UNSPSC 51162040 Beclometasone dipropionate/Formoterol fumarate/Glycopyrronium bromide is a Commodity code with minimal recent state and local procurement activity directly aligned to this specific combination pharmaceutical product. The recent opportunities tagged to this code do not substantively reflect procurement of this branded respiratory medication; instead, the most substantial opportunity—a City of Tucson Fire Department RFP for BLS/ALS pharmaceuticals and supplies (posted June 24, 2026, ITQ deadline June 24, 2026)—encompasses a broad range of emergency medical supplies, medications, and inventory management services across 251 line items estimated to support approximately 700 users. A second opportunity, Seminole County's IFB for Naloxone and Drug Deactivation Systems (posted June 30, 2026, ITB deadline July 26, 2023), targets opioid-response products rather than respiratory pharmaceuticals. A third, Pinellas County's ITQ for forensic drug standards (posted April 23, 2026), seeks certified reference materials for laboratory analysis, not clinical dispensing products. The remaining records in the source block are vendor forums, trade shows, networking events, and administrative notices unrelated to pharmaceutical procurement.

State and local governments buying under UNSPSC 51162040 appear to do so primarily through fire departments, emergency medical services, county health systems, and forensic laboratories rather than as discrete line items. The geographic spread of recent activity touches Florida (Seminole County, Pinellas County), Arizona (City of Tucson), and Texas (Williamson County administrative notices), though none of these opportunities specifically target beclometasone/formoterol/glycopyrronium combinations. The Tucson RFP is the largest and most relevant recent solicitation—a multi-year contract with federal funding (ARPA, HUD, FTA) carrying prevailing wage, Davis-Bacon, DBE, Buy America, and Section 3 compliance requirements, with pre-submittal meeting held June 10, 2026, and evaluation weighted heavily toward price (40 percent) and method of approach. Without demonstrated recent procurement activity directly tied to this specific pharmaceutical commodity, the code shows limited actionable opportunity at present; business development focus should track broader emergency medical supply and respiratory medication buys rather than expect isolated requisitions for this formulation.